AIM ImmunoTech (NYSE:AIM) Trading Down 7.5% – Time to Sell?

AIM ImmunoTech Inc. (NYSE:AIM)’s share price traded down 7.5% during trading on Tuesday . The stock traded as low as $0.11 and last traded at $0.12. 941,660 shares changed hands during trading, a decline of 24% from the average session volume of 1,246,432 shares. The stock had previously closed at $0.13.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets lowered their target price on shares of AIM ImmunoTech from $5.00 to $4.50 and set a “buy” rating on the stock in a research report on Tuesday, December 10th.

AIM ImmunoTech Price Performance

The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $8.52 million, a price-to-earnings ratio of -0.26 and a beta of -0.29. The company’s 50-day simple moving average is $0.19 and its 200 day simple moving average is $0.24.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).